Morgan Stanley Sees Upside for GoodRx Holdings Inc. (GDRX) in 2H

March 12, 2021 7:46 AM EST
Get Alerts GDRX Hot Sheet
Price: $38.14 -0.31%

Rating Summary:
    8 Buy, 5 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley analyst Ricky Goldwasser reiterated an Equalweight rating and $36.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX) after dampened utilization pressured 4Q MAC, but the analyst is looking through this and believes that as patients resume more normal behavior patterns and relationships with brand manufacturers kick into higher gear, there will be upside in 2H of the year.

The analyst stated "Implied guidance for rest if the year (2Q to 4Q) more aligned with the street implying 2Q to 4Q revenues of $586 million versus MS’ $588 million for same period and consensus’ $576 million. Guidance assumes utilization goes back to pre COVID baseline in 2H21, with new written scripts tracked by IQVIA will be key metric to watch to identify the inflection point."

For an analyst ratings summary and ratings history on GoodRx Holdings Inc. click here. For more ratings news on GoodRx Holdings Inc. click here.

Shares of GoodRx Holdings Inc. closed at $41.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Morgan Stanley